Proactive Investors - Run By Investors For Investors

ImmuPharma firmly committed to Lupuzor ahead of managed access programme

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM),says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.

Immupharma will get 'real-world' data from the MAP with up to 500 patients to receive the drug free of charge for two years.

That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.

One big advantage is that' real-world' data can be used to supplement a regulatory filing.

Merck's Keytruda I/O cancer treatment made use MAP extensively for example.

An extension study to Lupozor's phase III study will also report next year, said McCarthy.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full IMM profile View Profile

ImmuPharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use